
Abemaciclib 150 mg (Ramiven) is a targeted anticancer medicine used to treat certain types of hormone receptor-positive, HER2-negative breast cancer. It is commonly prescribed in combination with hormone therapy or, in some cases, as a single treatment. Abemaciclib helps slow the growth and spread of cancer cells, supporting improved disease control and long-term treatment management.
| Generic name | Abemaciclib |
| Strength | 150 mg |
| Manufacturer | Eli Lilly and Company |
| Package size | 14 Tablets |
| Used for | Hormone receptor-positive, HER2-negative breast cancer |
| Availability | In Stock |
| Shipping to | USA, UK, Australia, Canada, New Zealand, Philippines, Tunisia, France, Italy, South Korea, Albania, Romania, Hong Kong, Malaysia, Thailand, Singapore, UAE, Georgia, Armenia, Saudi Arabia, Qatar, Kuwait, South Africa, and many other countries. |
Abemaciclib is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor. It works by blocking proteins that help cancer cells grow and divide. By inhibiting these proteins, abemaciclib slows or prevents the multiplication of cancer cells, helping control tumour growth and disease progression.
Dr. Neeru Mehta holds a Doctor of Medicine (MD) degree and has a professional interest in oncology and cancer care. Her interests include cancer treatments, monitoring treatment progress, managing side effects and supportive care.